# Summary statistics - qualitative results

**EQA round: RF2/23 - Diagnostics of Rheumatoid Arthritis and ASLO**  Deadline: 29.9.2023

Setup: groups - measurement principle

| | |
|---|---|
| AV = assigned value | N$_{tot}$ = total number of the results |
| CVP = consensus of all participants | N$_{rel}$ = relative number of the results |
| >>> ... expected result | |
| > ... acceptable result | |
| ± ... result not assessed | |

| | |
|---|---|
| N$_{eva}$ = number of the results assessed | |
| N$_{suc}$ = number of successful results | |
| S$_{rel}$ = relative success | |

| Test / Sample / Group | AV | | N$_{tot}$ | N$_{rel}$ [%] | Result | N$_{eva}$ | N$_{suc}$ | S$_{rel}$ [%] |
|---|---|---|---|---|---|---|---|---|
| **(277) anti-CCP IgG** | | | 82 | | | 82 | 82 | 100 |
| **Sample A1** | | | 82 | | | 82 | 82 | 100 |
| (2) EIA (ELISA) | CVP | >>> | 32 | 39 | Negative | | | |
| (3) FIA (FEIA, TRACE) | CVP | >>> | 4 | 4,9 | Negative | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI) | CVP | >>> | 46 | 56 | Negative | | | |
| **Sample B1** | | | 82 | | | 82 | 82 | 100 |
| (2) EIA (ELISA) | CVP | >>> | 32 | 39 | Positive | | | |
| (3) FIA (FEIA, TRACE) | CVP | >>> | 4 | 4,9 | Positive | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI) | CVP | >>> | 46 | 56 | Positive | | | |
| **(282) anti-MCV** | | | 23 | | | 23 | 23 | 100 |
| **Sample A1** | | | 23 | | | 23 | 23 | 100 |
| (2) EIA (ELISA) | CVP | >>> | 22 | 96 | Negative | | | |
| (3) FIA (FEIA, TRACE) | CVP | >>> | 1 | 4,3 | Negative | | | |
| **Sample B1** | | | 23 | | | 23 | 23 | 100 |
| (2) EIA (ELISA) | CVP | >>> | 22 | 96 | Positive | | | |
| (3) FIA (FEIA, TRACE) | CVP | >>> | 1 | 4,3 | Positive | | | |
| **(231) Rheumat. fac. (scr)** | | | 169 | | | 169 | 167 | 99 |
| **Sample A1** | | | 169 | | | 169 | 167 | 99 |
| (2) EIA methods | CVP | >>> | 2 | 1,2 | Negative | | | |
| (3) IMT, IMN | CVP | >>> | 164 | 97 | Negative | | | |
| | | | 1 | 0,6 | Inconclusive result (borderline) | | | |
| | | | 1 | 0,6 | Positive | | | |
| (7) Semi-quan. aglut. m. | CVP | >>> | 1 | 0,6 | Negative | | | |
| **Sample B1** | | | 169 | | | 169 | 169 | 100 |
| (2) EIA methods | CVP | >>> | 2 | 1,2 | Positive | | | |
| (3) IMT, IMN | CVP | >>> | 166 | 98 | Positive | | | |
| (7) Semi-quan. aglut. m. | CVP | >>> | 1 | 0,6 | Positive | | | |
| **(234) Rheumat. factor IgA** | | | 47 | | | 47 | 47 | 100 |
| **Sample A1** | | | 47 | | | 47 | 47 | 100 |
| (0) Not specified | CVP | >>> | 47 | 100 | Negative | | | |
| **Sample B1** | | | 47 | | | 47 | 47 | 100 |
| (0) Not specified | CVP | >>> | 47 | 100 | Positive | | | |
| **(233) Rheumat. factor IgG** | | | 48 | | | 48 | 45 | 94 |
| **Sample A1** | | | 48 | | | 48 | 48 | 100 |
| (0) Not specified | CVP | >>> | 48 | 100 | Negative | | | |
| **Sample B1** | | | 48 | | | 48 | 45 | 94 |
| (0) Not specified | | | 3 | 6,3 | Negative | | | |
| | CVP | >>> | 45 | 94 | Positive | | | |
| **(235) Rheumat. factor IgM** | | | 47 | | | 47 | 47 | 100 |
| **Sample A1** | | | 47 | | | 47 | 47 | 100 |
| (0) Not specified | CVP | >>> | 47 | 100 | Negative | | | |
| **Sample B1** | | | 47 | | | 47 | 47 | 100 |
| (0) Not specified | CVP | >>> | 47 | 100 | Positive | | | |